Trauma surgeons’ role in gun violence prevention is hampered by restrictions on funding for research with implications for public health interventions.
AMA J Ethics. 2018; 20(5):475-482. doi:
10.1001/journalofethics.2018.20.5.msoc1-1805.
Although sharing health records with psychiatric patients may cause harm, clinicians also must consider beneficence and autonomy in making this decision.
AMA J Ethics. 2017; 19(3):253-259. doi:
10.1001/journalofethics.2017.19.3.ecas3-1703.
The greatest pressure to resuscitate the extremely low-birth-weight infant often results from successful marketing efforts that lead families to expect that their premature infants will be cute and healthy.
Anyone who has substantiated suspicion of ethical misconduct in research has a responsibility to report that suspicion to the appropriate authorities. He or she should not gossip about suspected misconduct with friends, colleagues, or others.
Public and private choices about allocation of funds for research raise a social-justice question: are these funding sources making fair decisions about where to invest their resources? The NIH has the clearest obligation to do so because it is taxpayer-supported.
The question that comes to mind when one considers the risks of a clinical trial is, “Why would anyone agree to participate?” Interviews with trial volunteers and their family members make clear that often it is the appeal of discovering something new and unknown.
Physicians new to a case might object to an established care plan. Practice variation, clinical momentum, and how value is assigned by different parties to acute care and comfort measures can each contribute to conflict in these cases.
AMA J Ethics. 2018; 20(8):E699-707. doi:
10.1001/amajethics.2018.699.
Nicole Martinez-Martin, JD, PhD, Laura B. Dunn, MD, and Laura Weiss Roberts, MD, MA
Calibrating a machine learning model with data from a local setting is key to predicting psychosis outcomes. Clinicians also need to understand an algorithm’s limitations and disclose clinically and ethically relevant information to patients.
AMA J Ethics. 2018; 20(9):E804-811. doi:
10.1001/amajethics.2018.804.
Clara C. Hildebrandt, MD and Jonathan M. Marron, MD, MPH
Gene editing with CRISPR/Cas9 raises concerns about equitable access to therapies that could limit research participation by minority group members. These concerns can be addressed through public education, transparency, and stakeholder partnerships.
AMA J Ethics. 2018; 20(9):E826-833. doi:
10.1001/amajethics.2018.826.